How to add GLP-1 weight management to a UK clinic in 2026 (oral and injectable)

Adding GLP-1 weight management to an existing UK clinic in 2026 is a logical service-line expansion as the category matures and the operational complexity drops with the arrival of oral semaglutide. The clinic keeps the patient relationship, adds a clinical pathway aligned with NICE guidance, and partners on dispensing rather than building pharmacy capability internally. This piece is the operator's brief for adding GLP-1 to a private GP, specialist, or multi-discipline clinic.

Why adding GLP-1 now is the right move

Three factors converge in 2026. Patient demand for medical weight management remains strong and growing. The category's clinical evidence base is well-established. Operational complexity has dropped materially with the arrival of oral semaglutide — no cold-chain requirement, simpler patient experience, lower per-dispense cost. Clinics that have considered adding weight management but balked at the cold-chain complexity now have a clearer entry path.

Adding GLP-1 also strengthens patient retention across the clinic. Weight management is a long-arc patient relationship — 6-18 month treatment courses with quarterly or semi-annual review — that maps well to private practice patient lifecycles. Patients who come for weight management often consume other services from the same clinic.

The clinical pathway you need to build

Aligned with NICE NG23 (Obesity) and NG87 (Weight management) where applicable. Intake assessment: BMI calculation, comorbidity screening (cardiovascular, diabetes, thyroid including MEN-2 family history, mental health, pregnancy status). Eligibility review against UKMEC-equivalent criteria for weight management prescribing. Informed consent including discussion of side effects and the off-licence considerations where they apply.

Ongoing pathway: three-month review for tolerability and early efficacy, then six-monthly review for continuation. Photographs and structured re-assessment where the patient or clinician find them useful. Annual or six-monthly metabolic blood work for many patients. The pathway should not auto-refill without scheduled review — this is the most common inspection-grade failure in the category.

Choosing between oral and injectable for your clinic

Both formats have a place in a clinic offering weight management. Oral semaglutide: easier patient experience (no injection, no fridge, no sharps), lower per-dispense cost, shorter operational ramp. Injectable: established efficacy data, longer track record, some patient preference for weekly dosing over daily oral.

Most clinics adding weight management in 2026 should offer both formats with clinician-guided patient choice. Patients with needle anxiety, complex daily routines that interfere with oral dosing, or preference for one over the other should be accommodated. Clinics that force a single format lose patients to multi-format competitors.

Dispensing — almost always partner, almost never build

Operating an in-house pharmacy to dispense GLP-1 for a clinic-scale weight management service is rarely the right call. The fixed costs of pharmacy operation (premises, superintendent, baseline staff, compliance) exceed what a clinic-scale weight management service can typically absorb. Partnering with a GPhC-registered pharmacy under a transparent per-dispense arrangement converts that fixed cost into variable cost.

PExpo's clinic model is built specifically for this — £0 platform fees with a transparent admin client care fee per request, covering pharmacist sign-off, picking, packing, courier handover, exception handling, and pharmacovigilance capture. Same-day dispatch on in-stock SKUs. The clinic keeps the patient relationship and patient-facing pricing; PExpo handles the dispensing layer.

Marketing and patient acquisition for clinic-added GLP-1

The advertising rules apply to clinic-added weight management exactly as they apply to dedicated weight management brands. Prescription-only medicines cannot be advertised to the public. The clinic can market the service, the consultation quality, the ongoing care model, the in-person follow-up where applicable. The clinic cannot name semaglutide, compare branded GLP-1s, or use testimonials for prescription products.

Existing patient base is the strongest acquisition channel for clinic-added GLP-1. Patients who trust the clinic for general primary care or specialist consultations are more likely to engage on weight management than cold-acquired patients. Internal cross-referral often produces a meaningful initial cohort while broader marketing ramps.

How PExpo's clinic model handles weight management dispensing

PExpo's clinic model dispenses both oral and injectable semaglutide alongside the broader UK licensed medicines range. The dispensing operation includes the cold-chain capability for injectable and standard dispensing for oral. Same-day dispatch on in-stock SKUs. £0 platform fees with transparent per-request admin client care fee.

For a clinic adding weight management in 2026, the typical add-on timeline via PExpo's clinic model is 2-4 weeks — meaningfully faster than building pharmacy capability internally or sourcing a new partner from scratch. See our clinic model page for the operational scope, our pricing page for the commercial structure, or our [launch guide for weight management with GLP-1](launch-uk-weight-management-clinic-glp1-2026.html) for broader category context.

Existing patient base is the strongest acquisition channel for clinic-added GLP-1. Patients who trust the clinic for general care engage more readily on weight management than cold-acquired prospects.

Adding GLP-1 weight management to a UK clinic in 2026 is a logical service-line expansion as the category matures and oral semaglutide reduces operational complexity. The clinic keeps the patient relationship, builds NICE-aligned clinical discipline, and partners on dispensing rather than building pharmacy capability. See our clinic model page for the £0-platform-fee dispensing partnership, our pricing page for the commercial structure, or the broader GLP-1 weight management launch guide.

Frequently asked questions